EMEA-002575-PIP02-20

Table of contents

Key facts

Invented name
Gavreto
Active substance
pralsetinib
Therapeutic area
Oncology
Decision number
P/0271/2021
PIP number
EMEA-002575-PIP02-20
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Treatment of thyroid cancer
Route(s) of administration
Oral use
Contact for public enquiries
Roche Registration GmbH

Tel. +41 6168 79411
E-mail: global.paediatrics@roche.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

How useful was this page?

Add your rating